🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
393

Quick answer

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Leuprorelin SR

    Takeda

    Prostatic Neoplasms, Locally Advanced

    phase 3 small molecule completed

    1 trial

  2. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 other completed

    1 trial

  3. Lifitegrast

    Takeda

    Dry Eye Disease

    phase 3 small molecule completed

    3 trials

  4. Lifitegrast

    Takeda

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    1 trial

  5. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    ADHD

    phase 3 small molecule completed

    3 trials

  6. Lisdexamfetamine dimesylate

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  7. Low-dose rtPA

    Takeda

    Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  8. Lu AA21004

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  9. Lubiprostone

    Takeda

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  10. Lubiprostone

    Takeda

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  11. MMX Mesalamine/Mesalazine (Low Dose)

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  12. MOVIPREP

    Takeda

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  13. Magnesium Pantoprazole

    Takeda

    GERD

    phase 3 small molecule completed

    1 trial

  14. Magnesium Pantoprazole 20 mg

    Takeda

    Gastric pH Control

    phase 3 small molecule terminated

    1 trial

  15. Maribavir

    Takeda

    Cytomegalovirus (CMV)

    phase 3 small molecule completed

    6 trials

  16. Matching Placebo for TAK-279 Dose A, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  17. Matching Placebo for TAK-279 Dose B, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose A

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  18. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  19. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  20. Mezagitamab

    Takeda

    Immune Thrombocytopenic Purpura (ITP)

    phase 3 small molecule active

    2 trials

  21. Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  22. Mezagitamab, Mezagitamab placebo-matching injection administered SC

    Takeda

    IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)

    phase 3 small molecule active

    1 trial

  23. Mezagitamab, Placebo matching for Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  24. Mixed salts of a single-entity amphetamine

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  25. Mixed salts of a single-entity amphetamine (ADDERALL XR)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  26. Motesanib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  27. NE-58095 IR

    Takeda

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  28. NPSP558

    Takeda

    Hypoparathyroidism

    phase 3 small molecule completed

    3 trials

  29. Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    4 trials

  30. OBI-1

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  31. OBI-1

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  32. Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  33. Ontamalimab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  34. Oral Budesonide Suspension (OBS)

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule completed

    2 trials

  35. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  36. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  37. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  38. Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  39. PEGylated Recombinant Factor VIII

    Takeda

    Hemophilia A

    phase 3 mab completed

    2 trials

  40. PEGylated Recombinant factor VIII (rFVIII)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  41. PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB

    Takeda

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  42. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  43. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  44. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE

    Takeda

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  45. PTH/Calcium

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  46. Pantoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule completed

    2 trials

  47. Pantoprazole

    Takeda

    GERD

    phase 3 small molecule completed

    1 trial

  48. Parathyroid Hormone (PTH)

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.